ReviewActas espanolas de psiquiatria2024
Is EEG Entropy a Useful Measure for Alzheimer's Disease?
Review in Actas espanolas de psiquiatria, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Entropy-Based Analysis of Olfactory EEG as a Candidate Biomarker for Early Mild Cognitive Impairment Detection: A Proof-of-Concept Study.Biosensors · 2026Article
- Multi-dimensional EEG analysis reveals distinct neurophysiological patterns in Alzheimer's and frontotemporal dementia.Journal of neuroengineering and rehabilitation · 2026Article
- Wavelet Entropy Analysis of EEG Signals During Wake and Sleep in Patients with Alzheimer's Disease: A Pilot Study.Neuropsychiatric disease and treatment · 2026Article
- Interpretable self-supervised transformers for resting-state EEG analysis in Alzheimer's disease.Frontiers in neuroinformatics · 2026Article
- Auditory Discrimination of Parametrically Sonified EEG Signals in Alzheimer's Disease.Journal of clinical medicine · 2025Article
- Feeding the mind: preliminary insights into the effects of Anthocyanin-Rich Extract from black carrots on brain activity and gut microbiota in patients with cognitive impairments.Scientific reports · 2025Article
- EEG biomarkers for Alzheimer's disease: A novel automated pipeline for detecting and monitoring disease progression.Journal of Alzheimer's disease : JAD · 2025Article
- The role of quantitative EEG biomarkers in Alzheimer's disease and mild cognitive impairment: applications and insights.Frontiers in aging neuroscience · 2025Review
- Identifying Features of Electroencephalography Associated with Improved Awareness in Persistent Vegetative State via Multiscale Entropy: A Machine Learning Modeling Study.Neurotrauma reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe number of individuals diagnosed with Alzheimer's disease (AD) has increased, and it is estimated to continue rising in the coming years. The diagnosis of this disease is challenging due to variations in onset and course, its diverse clinical manifestations, and the indications for measuring deposit biomarkers. Hence, there is a need to develop more precise and less invasive diagnostic tools. Multiple studies have considered using electroencephalography (EEG) entropy measures as an indicator of the onset and course of AD. Entropy is deemed suitable as a potential indicator based on the discovery that variations in its complexity can be associated with specific pathologies such as AD. METHODOLOGY: Following PRISMA guidelines, a literature search was conducted in 4 scientific databases, and 40 articles were analyzed after discarding and filtering.
resultsThere is a diversity in entropy measures; however, Sample Entropy (SampEn) and Multiscale Entropy (MSE) are the most widely used (21/40). In general, it is found that when comparing patients with controls, patients exhibit lower entropy (20/40) in various areas. Findings of correlation with the level of cognitive decline are less consistent, and with neuropsychiatric symptoms (2/40) or treatment response less explored (2/40), although most studies show lower entropy with greater severity. Machine learning-based studies show good discrimination capacity.
conclusionsThere is significant difficulty in comparing multiple studies due to their heterogeneity; however, changes in Multiscale Entropy (MSE) scales or a decrease in entropy levels are considered useful for determining the presence of AD and measuring its severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.